ImmunityBio Business Update and 2026 Financial Results

Events

Mar 3, 2026

Earnings Call Recording

Link to Webcast Recording

Materials discussed during earnings call

The following materials are referenced during the earnings call. Timestamps indicate when each item is discussed.

  1. General Investigational Plan (15:20)
    Download PDF
  2. ImmunityBio Platform (21:00)
    Download PDF
  3. NCI Workshop 2007 (21:25)
    Download PDF |
    View on SITC
  4. Mac Cheever Paper
    View on Wiley Online Library
  5. 2024 ASCO Slides (22:48)
    View on X
  6. Chris Cuomo Special (23:56)
    Watch on YouTube
  7. FDA Plausible Mechanism of Action (24:00)
    View on NEJM
  8. Cancer 2035 Talk by Dr. Patrick Soon-Shiong
    Watch on YouTube
  9. JAMA: Association of Lymphopenia with Risk of Mortality in General US Population
    View on JAMA Network Open
  10. The Ageing Immune System as a Driver of Systemic Ageing
    View on Nature
  11. Cancer Mind Map by Dr. Patrick Soon-Shiong
    Download PDF
  12. Keytruda Label June 2018
    Download PDF |
    View on FDA.gov

Contact us at

+1-844-MY NK CELLS (+1-844-696-5235)

Visit Newsroom

Solutions for Patients

ImmunityBio creates targeted, personalized immunotherapies that are designed to strengthen the immune system and enable it to outsmart your disease.

Opportunities for Trial Investigators

Next-generation adenovirus-vectored anti-cancer vaccines make appealing therapeutics for testing by trial investigators who want to make a contribution to clinical cancer research.

Tools for Research Scientists

Our NK-92® easy-to-maintain and highly cytotoxic natural killer cell line provides a versatile bioanalytical testing tool that can help researchers develop functional killing assays that are more consistent and reliable than donor blood and reporter gene assays.

ImmunityBio is continuously pursuing new immunotherapies designed to attack disease by enhancing the patient’s immune system, not weakening it.

About Us